Pharma must improve existing methods to boost solubility as “quantum leap” unlikely

By Nick Taylor

- Last updated on GMT

Related tags: Improve, Ceo

To boost solubility pharma must develop, refine and improve existing methods as a “quantum leap” in formulation is unlikely, Pharmaterials' CEO said.

Interest in boosting bioavailability has risen as compounds coming through development pipelines have become less soluble. However, improvements to formulation are expected to be gradual.

I don’t think I have seen a dramatically new approach to this. We will develop them, refine, improve, but perhaps not [make] a quantum leap​”, Graham Buckton, CEO of Pharmaterials, a subsidiary of Pii, and professor at the London School of Pharmacy, told in-PharmaTechnologist.

Pharma companies are likely to be receptive to improved techniques. Buckton gave the example of amorphous formulations which were around for decades before being used frequently by industry.

It’s become acceptable out of necessity I imagine​”, Buckton said.

Related news

Show more

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Follow us

Products

View more

Webinars